ESR1 and breast cancer: In preclinical models, long-term estrogen-deprived breast cancer cells show an up-regulation of the PI3K pathway leading to a ligand-independent activation of ER by its phosphorylation through the mTOR complex 1 (mTORC1)/S6K1 axis [26, 28].